Darryl Devivo
Neurology with Special Qualifications in Child Neurology · New York, NYNPI 1801806070
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.8%), education and consulting fees — rather than concentrated in one kind of arrangement. Novartis Gene Therapies, Inc. (fka Avexis, Inc.) accounts for 71.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $17,062 and has fallen 78.2% since, to $3,713 in 2025. Among neurology with special qualifications in child neurology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 117 payments — averaging $571.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$48K
- Biogen$8K
- Sarepta Therapeutics, Inc.$7K
- Novartis Pharma AG$4K
Across 184 payments — averaging $9968.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$712K
- Sarepta Therapeutics, Inc.$637K
- PTC Therapeutics, Inc.$224K
- Ultragenyx Pharmaceutical Inc.$219K
- Mallinckrodt Enterprises LLC$21K
- NS Pharma, Inc.$13K
- plus $9K from 4 others
What the payments were for
- Consulting fees$18,69128%
- Speaking & faculty fees$25,91939%
- Travel & lodging$1,2562%
- Food & beverage$3230%
- Education$20,64531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 108 | $48,018 |
| Biogen | 3 | $8,429 |
| Sarepta Therapeutics, Inc. | 5 | $6,674 |
| Novartis Pharma AG | 1 | $3,713 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOLGENSMA$49,924
- SPINRAZA$7,208
- Exondys 51$4,300
How this compares
$66,833 in reported general payments places this provider in the 95th percentile of 161 neurology with special qualifications in child neurology providers in New York.
See all neurology with special qualifications in child neurology providers in New York →
Other neurology with special qualifications in child neurology in New York
- Claudia ChiribogaNew York$220K
- Kaleb YohayNew York$125K
- Heather LauNew York$103K
- Mary Lynn ChuNew York$66K
- Gurcharanjeet KaurNew York$40K
- Jahannaz DastgirNew York$28K
- Naomi LubarrNew York$16K
- Tristan SandsNew York$12K
- Divya JayaramanNew York$10K
- Asim ShahidNew York$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.